Champions Oncology Inc (OTCMKTS:CSBR) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday.

Champions Oncology (OTCMKTS:CSBR) traded up 1.5802% during trading on Friday, reaching $2.6614. The company’s stock had a trading volume of 210 shares. The company has a 50 day moving average price of $2.45 and a 200-day moving average price of $2.98. The company’s market capitalization is $29.22 million. Champions Oncology has a 52 week low of $1.11 and a 52 week high of $4.79.

TRADEMARK VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/06/23/champions-oncology-inc-csbr-upgraded-to-hold-at-valuengine.html.

Champions Oncology Company Profile

Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.